ELDNEledon Pharmaceuticals, Inc.Healthcare · Biotechnologyas of 2026-09-17
Horizon

Issued 2026-09-17 at $2.65 · now $2.62 (2026-09-18, −1.1% since)

Based on its own history, a month from the 2026-09-17 close, ELDN has typically landed between $1.95 and $3.72 — a range of −26.5% to +40.4% from the issuance price $2.65.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,995 overlapping 1 month windows · 2014-09-172026-08-18 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,377 obs).

The cone is anchored at the 2026-09-17 issuance close ($2.65) — the price the forecast resolves against on 2026-10-16, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ELDN has typically landed a month from the 2026-09-17 close of $2.65 — the range is history, not a prediction.

$1.95worst · -26.5%$3.72best · +40.4%
  • now $2.62 (-1.1%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.62 (-1.1%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.28$2.96
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.95$3.72
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,996 windows spanning 2014-09-17 to 2026-09-18. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2016-06-30−80.4%−80.4%+5.1%
2016-06-24−80.1%−80.1%+6.4%
2016-07-12−80.1%−81.3%+0.0%
3 best
2020-04-15+185.5%+0.0%+185.5%
2018-12-31+168.8%+0.0%+168.8%
2020-09-04+165.9%+0.0%+170.8%

2,996 overlapping windows · 2014-09-172026-09-18 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~12 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
42%
+16.6%
n=12
Feb
58%
−0.1%
n=12
Mar
42%
−4.4%
n=12
Apr
33%
+0.9%
n=12
May
50%
+12.8%
n=12
Jun
25%
−16.5%
n=12
Jul
42%
−8.6%
n=12
Aug
25%
−4.2%
n=12
Sep
25%
+6.8%
n=12
Oct
50%
+9.5%
n=12
Nov
50%
−6.9%
n=12
Dec
17%
−9.4%
n=12

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$4$1↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2024-10-29BVF PARTNERS L P/ILdirectorPurchase2,213,816 @ $3.65$8.1M+42.6% of holding+15.7%−5.8%7,415,596Form 4 · filed 2 days after the trade
2024-10-29BVF PARTNERS L P/ILdirectorPurchase2,100,244 @ $3.65$7.7M+50.8% of holding+15.7%−5.8%6,235,545Form 4 · filed 2 days after the trade
2024-10-29BVF PARTNERS L P/ILdirectorPurchase440,489 @ $3.65$1.6M+110.7% of holding+15.7%−5.8%838,507Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

39 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-31Gros David-Alexandre CdirectorWithheld for tax194,791168,663Form 4
2026-07-31Perrin StevendirectorWithheld for tax72,13881,215Form 4
2026-07-31Perrin StevendirectorAward / grant152,353153,353Form 4
2026-07-31Gros David-Alexandre CdirectorAward / grant354,454363,454Form 4
2026-01-10Kirk AllandirectorOption exercise3,4303,430Form 4
2026-01-10Kirk AllandirectorOption exercise3,4300Form 4
2026-01-10Hillson JandirectorOption exercise3,4303,430Form 4
2026-01-10Robinson James A. Jr.directorOption exercise3,4303,430Form 4
2026-01-10Lee JunedirectorOption exercise3,4303,430Form 4
2026-01-10Lee JunedirectorOption exercise3,4300Form 4
2026-01-10McBride John S.directorOption exercise3,4303,430Form 4
2026-01-10McBride John S.directorOption exercise3,4300Form 4
2026-01-10Hillson JandirectorOption exercise3,4300Form 4
2026-01-10Robinson James A. Jr.directorOption exercise3,4300Form 4
2026-01-10Katkin KeithdirectorOption exercise8,5758,575Form 4
2026-01-10Katkin KeithdirectorOption exercise8,5750Form 4
2025-01-10McBride John S.directorAward / grant3,4303,430Form 4
2025-01-10Hillson JandirectorAward / grant30,87030,870Form 4
2025-01-10Hillson JandirectorAward / grant3,4303,430Form 4
2025-01-10Kirk AllandirectorAward / grant3,4303,430Form 4
2025-01-10Lee JunedirectorAward / grant30,87030,870Form 4
2025-01-10Lee JunedirectorAward / grant3,4303,430Form 4
2025-01-10Perrin StevendirectorAward / grant243,000243,000Form 4
2025-01-10Perrin StevendirectorAward / grant27,00027,000Form 4
2025-01-10Little Paul SeanofficerAward / grant175,000175,000Form 4
2025-01-10Robinson James A. Jr.directorAward / grant3,4303,430Form 4
2025-01-10Smith Bryan E.officerAward / grant150,500150,500Form 4
2025-01-10Smith Bryan E.officerAward / grant64,50064,500Form 4
2025-01-10Katkin KeithdirectorAward / grant77,17577,175Form 4
2025-01-10Kirk AllandirectorAward / grant30,87030,870Form 4
2025-01-10Little Paul SeanofficerAward / grant75,00075,000Form 4
2025-01-10Katkin KeithdirectorAward / grant8,5758,575Form 4
2025-01-10Gros David-Alexandre CdirectorAward / grant600,000600,000Form 4
2025-01-10Gros David-Alexandre CdirectorAward / grant66,50066,500Form 4
2025-01-10McBride John S.directorAward / grant30,87030,870Form 4
2024-11-21Perrin StevendirectorAward / grant840,438840,438Form 4
2024-11-21Smith Bryan E.officerAward / grant474,350474,350Form 4
2024-11-21Gros David-Alexandre CdirectorAward / grant1,015,7431,015,743Form 4
2024-11-21Little Paul SeanofficerAward / grant525,032525,032Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.